Core Insights - ProMIS Neurosciences is advancing its lead antibody candidate PMN310 for Alzheimer's disease (AD) through a Phase 1b clinical trial, highlighting the urgent need for improved treatment options in the AD space [1][2][3] - The company reported a net income of $2.8 million for the fiscal year 2024, a significant turnaround from a net loss of $13.2 million in 2023, primarily due to a gain on the change in fair value of warrant liabilities [7][14] - ProMIS has expanded its intellectual property portfolio with 23 newly granted or allowed patents since January 2024, strengthening its position in the neurodegenerative disease market [2][3] Alzheimer's Disease Program (PMN310) - PMN310 is a humanized IgG1 antibody targeting toxic amyloid-beta oligomers, which are believed to drive AD progression [3][4] - The Phase 1b trial (PRECISE-AD) aims to enroll approximately 100 subjects across 22 sites in the U.S., with interim results expected in the first half of 2026 and topline results anticipated by the end of 2026 [3][4] - The Phase 1a trial demonstrated that PMN310 was well-tolerated and effectively crossed the blood-brain barrier, suggesting potential for target engagement in AD patients [4] Financial Highlights - As of December 31, 2024, ProMIS had cash and cash equivalents of $13.3 million, an increase from $12.6 million in 2023 [7][11] - Research and development expenses rose to $10.6 million in 2024 from $7.9 million in 2023, reflecting costs associated with clinical trials [7][14] - The company completed a PIPE financing in Q3 2024, providing initial funding of $30.3 million and potential additional funding of $92.4 million [7] Pipeline and Future Developments - ProMIS is also advancing programs for amyotrophic lateral sclerosis (ALS) with PMN267 and multiple synucleinopathies with PMN440, showcasing a diverse pipeline in neurodegenerative diseases [2][5][6] - The company plans to present preclinical data at upcoming conferences, further demonstrating its commitment to innovation in the field [4][5][6]

Core Insights - ProMIS Neurosciences Inc. is advancing its antibody therapeutics and vaccines targeting toxic misfolded proteins for neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) [1][9] - The company plans to present its findings at the 2025 Alzheimer's and Parkinson's Disease International Conference in Vienna, Austria, from April 1-4, 2025 [1][2] Research and Development - ProMIS has developed a computational modeling platform that aids in creating next-generation antibodies and targeted vaccines for neurodegenerative diseases [2] - Preclinical data suggests that vaccination with platform-derived epitopes and selective antibody targeting of misfolded toxic aggregates of TDP-43 may be a safe and effective treatment method [2] - The company identified four different conformational B cell epitopes of amyloid-beta oligomers (AβOs) through computational modeling, which are crucial in the development of an Alzheimer's vaccine [3] Preclinical Study Results - Immunization with a single conformational epitope, peptide 301, showed maximal reactivity against AD brain oligomers [4] - Vaccination against pathogenic species of alpha-synuclein (ASyn) demonstrated potential protection against synucleinopathies, preserving normal ASyn function while minimizing off-target effects [4][5] - The study on TDP-43 revealed that selective targeting of misfolded toxic aggregates could be a promising approach for treating diseases associated with TDP-43 proteinopathy [6][7] Product Information - PMN310 is a humanized monoclonal antibody designed to selectively target soluble amyloid-beta oligomers, which are believed to be the most toxic form of Aβ [8] - PMN310 has completed a Phase 1a clinical study and is currently in a Phase 1b clinical trial involving Alzheimer's disease patients [9]

CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced plans to deliver virtual oral presentations at the 2025 Alzheimer's and Parkison's Disease (AD/PD) Interna ...

Core Insights - ProMIS Neurosciences Inc. is set to present preclinical data on computationally-derived vaccines targeting neurodegenerative diseases at the AAN Annual Meeting in April 2025 [1][2] Group 1: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) [9] - The company utilizes a proprietary computational discovery platform, ProMIS™, to identify Disease Specific Epitopes on misfolded proteins [9] - PMN310, the lead product candidate, is a humanized monoclonal antibody designed to selectively bind toxic soluble amyloid-beta oligomers, which are believed to be a primary cause of neurodegeneration in AD [7][8] Group 2: Research and Development - The preclinical studies demonstrated that immunization with a single conformational epitope, peptide 301, resulted in maximal reactivity against AD brain oligomers [4] - The company is exploring a novel approach to vaccine design that targets misfolded toxic proteins, aiming to induce a specific immune response against amyloid-beta oligomers for AD and pathogenic alpha-synuclein for MSA [2][5] - Results indicated that vaccination with conformational B cell epitopes produced high-affinity antibodies with selectivity for pathogenic alpha-synuclein, preserving normal protein function [6] Group 3: Upcoming Presentations - ProMIS Neurosciences will present two key studies at the AAN Annual Meeting: - The first study focuses on optimizing Alzheimer's vaccine configuration to target toxic amyloid-beta oligomers, presented by Dr. Johanne Kaplan on April 9, 2025 [3] - The second study discusses the rational design of a vaccine for synucleinopathies, presented by Dr. Johanne Kaplan on April 8, 2025 [5]

CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 37th Ann ...

Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as A ...

Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer's Disease   Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as A ...

CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Guggenheim ...

CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Company's shareholders. Dear ...

Core Insights - ProMIS Neurosciences Inc. has initiated a Phase 1b clinical trial (PRECISE-AD) for its lead therapeutic candidate PMN310, targeting Alzheimer's disease [1][4] - PMN310 is a humanized IgG1 antibody designed to selectively target toxic oligomers of amyloid-beta, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA) [2][4] - The trial will involve 100 patients with mild cognitive impairment or early Alzheimer's, assessing safety, tolerability, and pharmacokinetics over 12 months [3][4] Company Overview - ProMIS Neurosciences is focused on developing antibody therapeutics for neurodegenerative diseases, utilizing a proprietary platform to identify disease-specific epitopes [7] - PMN310 is designed to bind specifically to toxic amyloid-beta oligomers, which are believed to drive Alzheimer's disease progression [5][7] - The company has completed a Phase 1a study demonstrating a favorable safety profile and is now advancing to Phase 1b [6][7] Clinical Trial Details - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study evaluating multiple ascending doses of PMN310 [4] - The study will monitor safety, tolerability, pharmacokinetics, and biomarkers, with assessments every three months and frequent MRI scans to check for ARIA [4][3] - Interim data from the trial is expected in the first half of 2026 [4]